{"entity":{"id":"ksq-004ex","kind":"drug","name":"KSQ-004EX","aka":[],"tldr":"KSQ-004EX is an experimental engineered immune-cell therapy from KSQ Therapeutics, in phase 1 trials for selected advanced solid tumours.","summary":"KSQ-004EX is an autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy from KSQ Therapeutics. Tumour-infiltrating lymphocytes with both the Regnase-1 and SOCS1 genes switched off by CRISPR/Cas9. Its phase 1/2 study (NCT06598371) is recruiting; the company's pipeline lists melanoma, lung, head and neck, colorectal, pancreatic and cervical cancers. OnCo has no Regnase-1 target record. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"KSQ Therapeutics pipeline","url":"https://ksqtx.com/pipeline/"},{"label":"ClinicalTrials.gov NCT06598371","url":"https://clinicaltrials.gov/study/NCT06598371"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["socs1"],"drugs":[],"companies":["ksq-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06598371"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"KSQ-004EX","modality":"Autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy","mechanism":"Tumour-infiltrating lymphocytes with both the Regnase-1 and SOCS1 genes switched off by CRISPR/Cas9.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ksq-004ex/","neighbours":{"target":[{"id":"socs1","kind":"target","name":"SOCS1","route":"/targets/socs1/"}],"company":[{"id":"ksq-therapeutics","kind":"company","name":"KSQ Therapeutics","route":"/companies/ksq-therapeutics/"}],"trial":[{"id":"nct06598371","kind":"trial","name":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","route":"/trials/nct06598371/"}]}}